Press Enter to search · Esc to close
A cluster of 2024–2025 papers is dragging biological-age science out of the speculative zone and into the realm of measurable prediction. The signal is real — but so are the caveats.
A new whole-exome analysis of 1,245 long-lived Germans finds rare variants clustering in the mTOR pathway — the same one rapamycin targets — offering rare human evidence for a mechanism mostly studied in animals.
Two new studies sharpen the picture of mTOR as an aging lever — pointing toward more precise ways to dial it down than blunt suppression.